(Q41294359)

29 September 2017

1 reference

title

Cholecystokinin in anxiety (English)

1 reference

29 September 2017

1 reference

van Megen HJ

1

1 reference

29 September 2017

Westenberg HG

series ordinal

2

1 reference

29 September 2017

den Boer JA

series ordinal

3

1 reference

29 September 2017

Kahn RS

series ordinal

4

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 November 1996

1 reference

European Neuropsychopharmacology

29 September 2017

published in

1 reference

29 September 2017

volume

6

1 reference

29 September 2017

issue

4

1 reference

29 September 2017

page(s)

263-280

1 reference

Cholecystokinin-4 and panic.

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

PD135158, a CCK-B antagonist, reduces "state," but not "trait" anxiety in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

N-terminal fragments of intestinal cholecystokinin: evidence for release of CCK-8 by cleavage on the carboxyl side of Arg74 of proCCK

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Excitatory effects of cholecystokinin in rat hippocampus: pharmacological response compatible with 'central'- or B-type CCK receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The cholecystokinin hypothesis of panic and anxiety disorders: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

CCK modulates inhibitory synaptic transmission in the solitary complex through CCKB sites

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin as a potent excitant of neurons of the dentate gyrus of rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Tolerance to the anti-avoidance properties of cholecystokinin-octapeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Anxiolytic effects of CCK-B antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Lactate vulnerability after alprazolam versus placebo treatment of panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Neurochemical investigation of the afferent pathway from the vagus nerve to the nucleus tractus solitarius in mediating the "satiety syndrome" induced by systemic cholecystokinin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Characteristics of 125I-Bolton-Hunter labelled cholecystokinin binding in human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Systemically administered cholecystokinin affects an evoked potential in the hippocampal dentate gyrus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Pentagastrin has panic-inducing properties in obsessive compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin-8 increases K(+)-evoked [3H] gamma-aminobutyric acid release in slices from various brain areas

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The effects of cholecystokinin-8 in the nucleus tractus solitarius.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Heterogeneity of CCK-B receptors involved in animal models of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. I. Evidence for competition with enkephalins for in vitro common degradation pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. III. Inactivation of CCK-8 by a phosphoramidon-sensitive endopeptidase

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin antagonists--a toxicologic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

On the distribution of cholecystokinin receptor binding sites in the human brain: an autoradiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Immunochemical evidence of cholecystokinin-like peptides in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Distribution of cholecystokinin-like peptides in the human-brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The distribution and some connections of cholecystokinin neurons in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin enhances the acoustic startle response in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin peptides produce marked reduction of dopamine turnover in discrete areas in the rat brain following intraventricular injection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin in human cerebrospinal fluid: concentrations, dynamics, molecular forms and relationship to fasting and feeding in health, depression and alcoholism.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

CO2 vulnerability in panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Subpopulations of GABAergic neurons containing parvalbumin, calbindin D28k, and cholecystokinin in the rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Pharmacologic models of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Autoradiographical detection of cholecystokinin-A receptors in primate brain using 125I-Bolton Hunter CCK-8 and 3H-MK-329.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Distribution of cholecystokinin-like immunoreactivity in the nervous system. Co-existence with classical neurotransmitters and other neuropeptides.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Distribution patterns of CCK and CCK mRNA in some neuronal and non-neuronal tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Development of CCK-B antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin tetrapeptide, proglumide and open-field behavior in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Effect of cholecystokinin tetrapeptide amide on the metabolism of 5-hydroxytryptamine in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin octapeptide excites dorsal horn neurons both in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

m-Chlorophenylpiperazine as a probe of serotonin function

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Behavioral indications for serotonin receptor hypersensitivity in panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Valproate treatment of panic disorder and lactate-induced panic attacks

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

GABAergic neurons containing the Ca2+-binding protein parvalbumin in the rat hippocampus and dentate gyrus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin antagonism by anthramycin, a benzodiazepine antibiotic, in the central nervous system in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Imipramine in the treatment of panic disorder and its complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Lactate provocation of panic attacks. I. Clinical and behavioral findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Possible mechanisms for lactate's induction of panic

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

CCK peptides and mRNA in the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Distribution of cholecystokinin mRNA and peptides in the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Evidence for cholecystokinin-like immunoreactive neurons in the rat medulla oblongata which project to the spinal cord.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Inhibitory effect of cholecystokinin octapeptide on neurons in the nucleus tractus solitarius

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Appetite regulation by gut peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Hormonal polypeptides of the upper intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Measurement of central nervous system activity of systemically administered CCKB receptor antagonists by ex vivo binding

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

5-Hydroxytryptophan Uptake by Dog Thyroid ‘C’ Cells, and its Possible Significance in Polypeptide Hormone Production

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localization

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Evaluation of the effects of PD 134308 (CI-988), A CCK-B antagonist, on the punished responding of squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Characterization of Cholecystokinin Binding Sites in Rat Cerebral Cortex Using a 125I-CCK-8 Probe Resistant to Degradation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Inhibition by 5-HT3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Release of cholecystokinin in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Benzodiazepines increase preprocholecystokinin messenger RNA levels in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Blockade by imipramine or desipramine of panic induced by sodium lactate

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Protection by serine peptidase inhibitors of endogenous cholecystokinin released from brain slices

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Interaction of cholecystokinin and diazepam: effects on brain monoamines.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin- or cholecystokinin- immunoreactive material

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin and neurotensin gradients in human CSF.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

A cholecystokinin-metabolizing enzyme in rat intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

On the significance of cholecystokinin receptors in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Separate populations of cholecystokinin and 5-hydroxytryptamine-containing neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Panic symptoms after inhalation of carbon dioxide.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

New peptide in the vertebrate CNS reacting with antigastrin antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Characterization of the release of cholecystokinin-8 from isolated nerve terminals and comparison with exocytosis of classical transmitters.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin octapeptide antagonized opioid analgesia mediated by mu- and kappa- but not delta-receptors in the spinal cord of the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Cholecystokinin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Functional role of brain CCK receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

An analysis of panic symptoms during hypercarbia compared to hypocarbia in patients with panic attacks

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2896%2900038-7

7 January 2021

10.1016/S0924-977X(96)00038-7

Identifiers

DOI

1 reference

29 September 2017

1 reference